Defective sindbis viral vectors

Details Defective sindbis viral vectors Defective sindbis viral vectors

2007-12-04

2007-12-04

Ton, Thaian N. (Department: 1632)

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Preparing compound containing saccharide radical

C435S320100, C536S023100

Reexamination Certificate

active

11392926

ABSTRACT:
Disclosed herein are new defective Sindbis viral vectors made from wild type Ar-339 Sindbis virus, with differences in replicase and envelope proteins between JT vectors and consensus Sindbis virus sequences, and also between JT and Ar-339 vectors. Also disclosed are plasmids used for the production of the vectors, methods for producing the vectors, methods for treating mammals suffering from tumors and pharmaceutical formulations for use in the treatment methods.

REFERENCES:
patent: 5091309 (1992-02-01), Schlesinger et al.
patent: 5217879 (1993-06-01), Huang et al.
patent: 5739026 (1998-04-01), Garoff
patent: 5789245 (1998-08-01), Dubensky, Jr. et al.
patent: 5814482 (1998-09-01), Dubensky, Jr. et al.
patent: 5843723 (1998-12-01), Dubensky, Jr. et al.
patent: 6015686 (2000-01-01), Dubensky, Jr. et al.
patent: 6015694 (2000-01-01), Dubensky, Jr. et al.
patent: 6190666 (2001-02-01), Garoff et al.
patent: 6224879 (2001-05-01), Sjoberg
patent: 6242259 (2001-06-01), Polo et al.
patent: 6329201 (2001-12-01), Polo et al.
patent: 6342372 (2002-01-01), Dubensky, Jr. et al.
patent: 6376236 (2002-04-01), Dubensky, Jr. et al.
patent: 6391632 (2002-05-01), Dubensky, Jr. et al.
patent: 6426196 (2002-07-01), Dubensky, Jr. et al.
patent: 6451592 (2002-09-01), Dubensky, Jr. et al.
patent: 6458560 (2002-10-01), Dubensky, Jr. et al.
patent: 6465634 (2002-10-01), Dubensky, Jr. et al.
patent: 6566093 (2003-05-01), Liljestrom et al.
patent: 6592874 (2003-07-01), Schlesinger et al.
patent: 6692750 (2004-02-01), Sjoberg et al.
patent: 6730297 (2004-05-01), Davidson et al.
patent: 6770283 (2004-08-01), Garoff et al.
patent: 99/18226 (1999-04-01), None
patent: 99/18799 (1999-04-01), None
patent: 99/44423 (1999-09-01), None
patent: 00/62735 (2000-10-01), None
NCBI GenBank Locus SINCG, Version J02363.1, 11703 bp ss-RNA linear VRL Oct. 25, 2000.(9 pages).
Ying H. et al., Cancer Therapy Using a Self-Replicating RNA Vaccine, Nature Medicine, Jul. 1999, pp. 823-827, vol. 5, No. 7, Nature Publishing Group, New York, USA.
Schlesinger S. et al., “Alphavirus Vectors for Gene Expression and Vaccines”, Current Opinion in Biotechnology, Oct. 1999, pp. 434-439, vol. 10, No. 5, London, GB.
Perri, Slyvia et al. “Replicon Vectors Derived from Sindbis Virus and Semliki Forest Virus That Establish Persistent Replication in Host Cells.” Journal of Virology, Oct. 2000, pp. 9802-9807, vol. 74, No. 20.
Leitner, Wolfgang W. et al. “Enhancement of Tumor-specific Immune Response With Plasmid DNA Replicon Vectors.” Cancer Research, Jan. 1, 2000, pp. 51-55.
Hariharan, Mangala J. et al. “DNA Immunization Againstr Herpes Simplex Virus: Enhanced Efficacy Using a Sindbis Virus-Based Vector.” Journal of Virology, Feb. 1998, pp. 950-958, vol. 72, No. 2.
Gardner, Jason P. et al. “Infection of Human Dendritic Cells by a Sindbis Virus Replicon Vector Is Determined by a Single Amino Acid Substitution in the E2 Glycoprotein.” Journal of Virology, Dec. 2000, pp. 11849-11857, vol. 74, No. 24.
Polo, John M. et al. “Stable Alphavirus Packaging Cell Lines for Sindbis Virus- and Semliki Forest Virus-Derived Vectors.” Proc. Natl. Acad. Sci. USA, Apr. 1999, pp. 4598-4603, vol. 96.
Dubensky, Thomas W., Jr. et al. “Sindbis Virus DNA-Basd Expression Vectors: Utility for In Vitro and In Vivo Gene Transfer.” Journal of Virology, Jan. 1996, pp. 508-519, vol. 70, No. 1.
Xiong, Cheng et al. “Sindbis Virus: An Efficient, Broad Host Range Vector for Gene Expression in Animal Cells.” Science, Mar. 3, 1989, pp. 1188-1191, vol. 243.
Levis, Robin et al. “Engineered Defecctive Interfering RNAs of Sindbis Virus Express Bacterial Chloramphenicol Acetyltransferase in Avian Cells.” Porc. Natl. Acad. Sci. USA, Jul. 1987, pp. 4811-4815, vol. 84.
Murphy A-M et al. “Inhibition of Human Lung Carcinoma Cell Growth by Apoptosis Using Semliki Forest Virus Recombinant Particles.” Gene Therapy, 2000, p. 1477-82, vol. 7.
Asselin-Paturel C. et al. “Transfer of the murine IL-12 gene in vivo by a Semiliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitered by Doppler ultrasonography” Gene Therapy, 1998, p. 615, vol. 5.
Klimp et al. “Activation of Peritoneal Cells Upon in Vivo Transfection with a Recumbinant Alphavirus Expressing GM-CSF.” Gene Therapy, Feb. 2000, p. 300-7, vol. 8, No. 4.
Li et al. “Rescue of Sindbis Virus-Specific RNA Replication and Transcription by using Vaccinia Virus Recombinant.” J. of Virology, Dec. 1991, p. 6714-23, vol. 65, No. 12.
Cheng et al. “Cancer Immunotherapy using Sindbis Virus Replicon Particles Encoding VP22-Antigen Fusion.” Human Gene Therapy, Mar. 1, 2002, p. 553-68, vol. 13, No. 4.
Velders et al. “Eradication of Established Tumors by Vaccination with Venezuelan Equine Encephalitis Virus Replicon Particles Delivering Human Papilomavirus 16 E7 RNA.” Cancer Research, Nov. 1, 2001, p. 7861-67, vol. 61, No. 21.
Smerdou et al. “Two-Helper System for Production of Recombinant Semliki Forest Virus Particles.” Journal of Virology, vol. 73, No. 2, Feb. 1999, pp. 1092-1098.
Zhang, et al. “Cloning of Human IL-12 p40 and p35 DNA into the Semliki Forest Virus Vector: Expression of IL-12 in Human Tumor Cells.” Gene Therapy, 1997, pp. 367-374.
Alemany, et al. “Blood Clearance Rates of Adenovirus Type 5 in Mice.” Journal of General Virology, 2000, pp. 2605-2609.
Sung, et al. “TNFa and IFNg Induced by Innate Anti-Adenoviral Immune Responses Inhibit Adenovirus-Mediated Transgene Expression.” Molecular Therapy, vol. 3, No. 5, May 2001, pp. 757-767.
Unno, et al. “Oncolytic Viral Therapy for Cervical and Ovarian Cancer Cells by Sindbis Virus AR339 Strain.” Clin. Cancer. Res., vol. 11, No. 12, Jun. 15, 2005, pp. 4553-4560.
Pouton, et al. “Key Issues in Non-Viral Gene Delivery.” Advanced Drug Delivery Reviews, 2001, pp. 187-203.
Read, et al. “Barriers to Gene Delivery Using Synthetic Vectors.” Advances in Genetics, vol. 53, 2005, pp. 19-46.
Higashikawa, et al. “Kinetic Analyses of Stability of Simple and Complex Retorviral Vectors.” Virology 280, 2001, pp. 124-131.
DePolo, et al. “The Resistance of Retroviral Vectors Produced from Human Cells to Serum Inactivation In Vivo and In Vitro Is Primate Species Development.” Journal of Virology, Aug. 1999, pp. 6708-6714.
Miller, et al. “Targeted Vectors for Gene Therapy.” The FASEB Journal, vol. 9, Feb. 1995, pp. 190-199.
Deonarain, “Ligand-Targeted Receiptor-Mediated Vectors for Gene Delivery.” Exp. Opin. Ther. Patents, vol. 8, No. 1, 1998, pp. 53-69.
Verma, et al. “Gene Therapy—Promises, Problems and Prospects.” Nature, vol. 389, Sep. 18, 1997, pp. 239-242.
Crystal, “Transfer of Genes to Humans: Early Lessons and Obstacles to Success.” Science, vol. 270, Oct. 20, 1995, pp. 404-410.
Frolov, et al. “Comparison of the Effects of Sindbis Virus and Sindbis Virus Replicons on Host Cell Protein Synthesis and Cytopathogenicity in BHK Cells.” Journal of Virology, vol. 68, No. 3, Mar. 1994, pp. 1721-1727.

Affiliated with

Also associated with

Rating

Defective sindbis viral vectors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Defective sindbis viral vectors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Defective sindbis viral vectors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3863912